Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Studies from Utrecht University, Institute of Biomembranes reveal new findings on cancer therapy
March 2nd, 2007
Research findings, "Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies," are discussed in a new report. According to recent research from Utrecht, Netherlands, "The development of a number of different solid tumours is associated with over-expression of ErbB1, or the epidermal growth factor receptor (EGFR), and this over-expression is often correlated with poor prognosis of patients. Therefore, this receptor tyrosine kinase is considered to be an attractive target for antibody-based therapy." "Indeed, antibodies to the EGFR have already proven their value for the treatment of several solid tumours, especially in combination...
Source: Drug Week (2007-03-02)
|
